Promoter holding
64.27%
SL
Suven Life Sciences Limited - Due diligence report
A 360° intelligence report on Suven Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress si…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Suven Life Sciences — 360° Intelligence Report
Generated from MCA filings & public records70/100
Trust Score
Moderate
Suven Life Sciences is assessed as Moderate with a Trust Score of 70/100. Suven Life Sciences is an active public limited indian non-government company incorporated in 1989, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Suven Life Sciences Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
42/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 50/100 Moderate
- Negative operating earnings - debt service depends on external support.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
Charges position: 0 open (-) · 14 satisfied (239.04 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| State Bank Of India | 5 | 48.0 cr |
| Bank Of Bahrain And Kuwait Bsc | 2 | 48.0 cr |
| Bank Of India | 1 | 48.0 cr |
| State Of Bank Patiala | 1 | 48.0 cr |
| Industrial Development Bank Of India | 1 | 48.0 cr |
| Export -- Import Bank Of India | 1 | 48.0 cr |
Compliance Score: 42/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: BSE.
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (1 disclosure(s)).
- 2 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SANTANU MUKHERJEE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MOHAN KUMAR MALLARAPU | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUDHARANI JASTI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATESWARLU JASTI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VAJJA SAMBASIVA RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SEYED EHTESHAM HASNAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Shrenik Soni | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANANTHASAI PADMAJA JASTHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Jasti Property And Equity Holdings Private Limited
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Suven Neurosciences Inc | Subsidiary Company | 74.00% |
| Jasti Property And Equity Holdings Private Limited | Holding Company | 74.00% |
Key managerial personnel: MOHAN KUMAR MALLARAPU (CFO) · SUDHARANI JASTI (Whole-time director) · VENKATESWARLU JASTI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 60 · Distress 90
Growth signals & trust indicators
Latest year revenue grew 38%.
Asset base grew 1.42 - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 37+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (42/100).
MSME payment delays disclosed - latest outstanding 1.95 Lakh.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence65/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment51/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view62/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events22 Aug 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
05 May 2024
Director ceased
VENKATESWARLU JASTI
04 Mar 2024
Director ceased
VAJJA SAMBASIVA RAO
30 Jan 2024
Director appointed
VAJJA SAMBASIVA RAO (Director)
16 Nov 2022
Securities allotted
72691239 Equity Shares - 399.80 cr raised
28 Mar 2022
Securities allotted
18100000 Equity Shares - 147.64 cr raised
02 Nov 2021
Director ceased
KUKUDALA RAVI
07 Jan 2021
Charge satisfied
Bank Of Bahrain And Kuwait Bsc
03 Dec 2020
Charge satisfied
State Bank Of India
10 Jan 2020
Director appointed
MOHAN KUMAR MALLARAPU (CFO)
Director appointed
Shrenik Soni (Company Secretary)
Director ceased
HANUMANTHA RAO KOKKONDA
Director ceased
SUBBA RAO PARUPALLY
20 Mar 2019
Director ceased
ANANTHASAI PADMAJA JASTHI
10
Key Observations
Auto-generated from the data aboveRevenue declined 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Net worth is positive.
8 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
All 14 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
59 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Esri | U72500DL2019FTC346672 | New Delhi, Delhi, India |
| Dabur Research | U73100DL1979NPL010092 | New Delhi, Delhi, India |
| Infrasupport Engineering Consultants Private Limited | U45202KA2009PTC050188 | Bangalore, Karnataka, India |
| Jdm Research | U73200WB2012PTC181220 | Kolkata, West Bengal, India |
| Veol Medical Technologies | U73100MH2008PTC187836 | Navi Mumbai, Maharashtra, India |
| Admerus Biosciences Private Limited | U74900TG2015PTC133392 | Hyderabad, Telangana, India |
| Atonarp | U33110KA2015FTC079569 | Bangalore North, Karnataka, India |
| Integral Biosciences | U73100DL2007PTC162147 | New Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Suven Life Sciences before audits and certifications: compliance score 42/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Suven Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 60/100, margin trends, ownership structure and peer set for Suven Life Sciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Suven Life Sciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Suven Life Sciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Suven Life Sciences an active company?
Suven Life Sciences has MCA status “Active” with a compliance score of 42/100 (Caution Indicated).
Is Suven Life Sciences financially healthy?
Suven Life Sciences has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.
Should I do business with Suven Life Sciences?
Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Suven Life Sciences?
The ultimate holding entity is Jasti Property And Equity Holdings Private Limited. 8 active director(s) are on record.
Does Suven Life Sciences have loans or charges against its assets?
No open charges - all 14 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Suven Life Sciences up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 42/100 (Caution Indicated).
Is it risky to lend to Suven Life Sciences?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
